Neither company has disclosed brand names, pricing or launch timelines, but industry watchers expect them to emerge as fast followers, leveraging their established diabetes portfolios and doctor networks to compete aggressively on price once multiple generics hit the market in Q1 FY27
The market is going to explode once the biosimilar versions hit the market and affordability increases
Semaglutide has been associated with reduction in liver fat and inflammation, potentially reversing certain types of liver damage
Milligrams measure drug weight
It includes: One-on-one physician consultation Ongoing monthly clinical oversight and provider support Access to compounded GLP-1/GIP injections (if medically appropriate) Monthly medication supply from a licensed compounding pharmacy Optional wellness add-ons: lab testing, nutritional guidance, and more *Program starts at $400/month Who May Qualify This program may be appropriate for individuals who: Have a BMI of 30+, or 27+ with a related health condition Have not achieved success with other weight loss methods May not be candidates for brand-name GLP-1/GIP medications Want a clinically guided, structured approach to weight loss A thorough medical consultation will determine your eligibility and treatment plan
